NEW YORK (GenomeWeb) – Israeli biotech firm Can-Fite BioPharma announced today an agreement with Smart Assays to develop a biomarker blood test kits for the A3 adenosine receptor (A3AR).

Molecular biology labs would be able to use Can-Fite's A3AR biomarker kit to identify a patient's response to the firm's drugs. A3AR is present in high concentrations in inflammatory cells and cancer cells, and Can-Fite's drugs target and bind to A3AR, causing cell apoptosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.